115 related articles for article (PubMed ID: 3493611)
1. The relationship of HLA-DR3 and outcome after antithyroid drugs to the IgG subclass distribution of thyroid autoantibodies in Graves' disease.
Weetman AP; Cohen SB
Acta Endocrinol (Copenh); 1987 Feb; 114(2):292-7. PubMed ID: 3493611
[TBL] [Abstract][Full Text] [Related]
2. Prediction of outcome in Graves' disease after carbimazole treatment.
Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
[TBL] [Abstract][Full Text] [Related]
3. IgG subclass distribution of thyroid autoantibodies: a 'fingerprint' of an individual's response to thyroglobulin and thyroid microsomal antigen.
McLachlan SM; Feldt-Rasmussen U; Young ET; Middleton SL; Dlichert-Toft M; Siersboek-Nielsen K; Date J; Carr D; Clark F; Rees Smith B
Clin Endocrinol (Oxf); 1987 Mar; 26(3):335-46. PubMed ID: 3652478
[TBL] [Abstract][Full Text] [Related]
4. The IgG subclass distribution of thyroid autoantibodies.
Weetman AP; Cohen S
Immunol Lett; 1986 Nov; 13(6):335-41. PubMed ID: 3781568
[TBL] [Abstract][Full Text] [Related]
5. IgG heavy-chain subclass restriction of thyrotropin-binding inhibitory immunoglobulins in Graves' disease.
Weetman AP; Byfield PG; Black C; Reimer CB
Eur J Clin Invest; 1990 Aug; 20(4):406-10. PubMed ID: 1977589
[TBL] [Abstract][Full Text] [Related]
6. Thyroglobulin autoantibodies switch to immunoglobulin (Ig)G1 and IgG3 subclasses and preserve their restricted epitope pattern after 131I treatment for Graves' hyperthyroidism: the activity of autoimmune disease influences subclass distribution but not epitope pattern of autoantibodies.
Latrofa F; Ricci D; Montanelli L; Piaggi P; Mazzi B; Bianchi F; Brozzi F; Santini P; Fiore E; Marinò M; Tonacchera M; Vitti P
Clin Exp Immunol; 2014 Dec; 178(3):438-46. PubMed ID: 25134846
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin G subclasses of anti-thyroid peroxidase autoantibodies in human autoimmune thyroid diseases.
Kotani T; Kato E; Hirai K; Kuma K; Ohtaki S
Endocrinol Jpn; 1986 Aug; 33(4):505-10. PubMed ID: 3792276
[TBL] [Abstract][Full Text] [Related]
8. [Distribution of IgG subclasses of TgAb and TPOAb in sera from patients with Graves' disease, Graves' disease plus Hashimoto's thyroiditis and Hashimoto's thyrotoxicosis].
Yuan S; Yu N; Gao Y; Huang W; He Y; Dong B; Lu G; Li M; Cai X; Peng D; Wang Y; Li T; Huang Y; Gao Y; Guo X; Shi B
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(2):110-4. PubMed ID: 24721350
[TBL] [Abstract][Full Text] [Related]
9. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease.
Wilson R; McKillop JH; Henderson N; Pearson DW; Thomson JA
Clin Endocrinol (Oxf); 1986 Aug; 25(2):151-6. PubMed ID: 3491692
[TBL] [Abstract][Full Text] [Related]
10. Expression of HLA-DR antigens by thyroid cells: the effect of Graves' IgG.
Bodolay E; Szegedi G; Suranyi P; Juhasz F; Stenszky V; Balazs C; Farid NR
Immunol Lett; 1987 May; 15(1):77-81. PubMed ID: 3111991
[TBL] [Abstract][Full Text] [Related]
11. Prediction of remission after antithyroid drug treatment in Graves' disease.
Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
[TBL] [Abstract][Full Text] [Related]
12. Do HLA-DR-typing and measurement of TSH-receptor antibodies help in the prediction of the clinical course of Graves' thyrotoxicosis after antithyroid drug treatment?
Schleusener H; Schwander J; Holl G; Badenhoop K; Hensen J; Finke R; Schernthaner G; Mayr WR; Kotulla P
Acta Endocrinol Suppl (Copenh); 1987; 281():318-24. PubMed ID: 2441554
[TBL] [Abstract][Full Text] [Related]
13. T lymphocyte subsets at various stages of hyperthyroid Graves' disease: effect of carbimazole treatment and relationship with thyroid-stimulating antibody levels or HLA status.
Madec AM; Allannic H; Genetet N; Gueguen M; Genetet G; Fauchet R; Stefanutti A; Orgiazzi J
J Clin Endocrinol Metab; 1986 Jan; 62(1):117-21. PubMed ID: 3484386
[TBL] [Abstract][Full Text] [Related]
14. Insulin autoantibodies in Graves' disease--before and after carbimazole therapy.
Armitage M; Franklyn J; Scott-Morgan L; Parr J; Borsey DQ; Sheppard M; Wilkin TJ
Diabetes Res Clin Pract; 1990 Mar; 8(3):169-76. PubMed ID: 2340791
[TBL] [Abstract][Full Text] [Related]
15. Affinity purification of IgG subclasses and the distribution of thyroid auto-antibody reactivity in Hashimoto's thyroiditis.
Weetman AP; Black CM; Cohen SB; Tomlinson R; Banga JP; Reimer CB
Scand J Immunol; 1989 Jul; 30(1):73-82. PubMed ID: 2756340
[TBL] [Abstract][Full Text] [Related]
16. Isotype and immunoglobulin subclass distribution of eye muscle membrane reactive antibodies in the serum of patients with thyroid-associated ophthalmopathy as detected in Western blotting.
Bernard NF; Ertug F; Teboul N; Zhang ZG; Salvi M; Wall JR
Autoimmunity; 1991; 10(1):57-63. PubMed ID: 1742423
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of the relationship between relapse of hyperthyroid Graves' disease after antithyroid drugs and HLA haplotype.
Allannic H; Fauchet R; Lorcy Y; Gueguen M; Le Guerrier AM; Genetet B
J Clin Endocrinol Metab; 1983 Oct; 57(4):719-22. PubMed ID: 6688428
[TBL] [Abstract][Full Text] [Related]
18. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease.
Schleusener H; Schwander J; Fischer C; Holle R; Holl G; Badenhoop K; Hensen J; Finke R; Bogner U; Mayr WR
Acta Endocrinol (Copenh); 1989 Jun; 120(6):689-701. PubMed ID: 2567102
[TBL] [Abstract][Full Text] [Related]
19. A primary standard for the ELISA of thyroglobulin and microsomal autoantibody IgG subclass associated activity.
Parkes AB; Howells RD; Mower J; Hall R
J Clin Lab Immunol; 1989 Nov; 30(3):141-5. PubMed ID: 2642171
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse.
Weetman AP; Pickerill AP; Watson P; Chatterjee VK; Edwards OM
Q J Med; 1994 Jun; 87(6):337-41. PubMed ID: 7913766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
